Editas Medicine (EDIT) Institutional Ownership

71.90% of Editas Medicine's stock is owned by institutional investors. Learn more on EDIT's institutional investor holdings.

Of the 108 institutional investors that purchased Editas Medicine's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BlackRock Inc. ($10.59M), ADAR1 Capital Management LLC ($8.89M), Renaissance Technologies LLC ($4.15M), Seven Fleet Capital Management LP ($2.66M), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($1.70M), Jacobs Levy Equity Management Inc. ($1.22M), and Balyasny Asset Management L.P. ($1.13M).

Institutional investors have bought a total of 32,413,024 shares in the last 24 months. This purchase volume represents approximately $99.89M in transactions.

Of the 31 institutional investors that sold Editas Medicine's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Millennium Management LLC ($1.71M), Dimensional Fund Advisors LP ($1.07M), Stifel Financial Corp ($535.44K), JPMorgan Chase & Co. ($490.11K), Royal Bank of Canada ($345.99K), UBS Group AG ($207.97K), and Vanguard Group Inc. ($193.87K).

Institutional investors have sold a total of 5,238,191 shares in the last 24 months. This volume of shares sold represents approximately $15.17M in transactions.